GET DAILY SIGNALSCrescent Capital BDC (CCAP) and the Case for Reaching an $11 Price Target
Key Takeaways
- The central $11 stock price target is the arithmetic mean of the five most recent analyst targets reviewed ($10.85), rounded to a clean figure.
- It is built from current targets issued between August and October 2026 by Raymond James, Clear Street, Bank of America, KBW, and Wells Fargo, which range from $10 to $12.
- With the shares recently trading near $9.38, the target implies roughly 17% upside — a substantial move, not a trivial one.
- The strongest supports are an unusually deep discount to net asset value, a new $50 million buyback, and fee reductions that improve shareholder alignment.
- The biggest risks are eroding book value, thin dividend coverage after a 19% base-dividend cut, and elevated non-accrual loans.
- For more on this company, explore Major News, Today's Price Move, the Forecast, and Earnings pages for the latest developments.
- To monitor changing technical conditions and discover new opportunities, explore Trending AI Robots.
Analyst Price Targets and Consensus View
CCAP, the ticker for Crescent Capital BDC, Inc., is a business development company (BDC) — a lender to middle-market companies that passes most of its income to shareholders as dividends. Because BDCs are valued heavily on their net asset value (NAV), or book value per share, analyst targets reflect both earnings power and expectations for how wide a discount to NAV the market will tolerate.
The five most recent analyst price targets reviewed — Raymond James at $10 (October 22, 2026), Clear Street at $11 (October 21), Bank of America at $10.25 (September 10), KBW at $12 (August 17), and Wells Fargo at $11 (August 12) — average about $10.85, which rounds to the $11 central target used here. That is a tight range of $10 to $12, reflecting a cautious outlook after a year of cuts and downgrades. Bank of America moved to a Hold and KBW to Market Perform, while Raymond James and Clear Street kept Buy ratings but lowered their targets. Analysts cite lingering credit concerns and a declining NAV, tempered by the stock's discount to peers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For context, older targets from earlier in 2026 remain in some aggregators — Ladenburg Thalmann at $15 and Oppenheimer at $16 from May 2026, for example — which is why published "consensus" figures vary from roughly $10.85 to $12.25. The recent revisions cluster much lower, near $10–$12.
Current Market Position and Path Toward the Target
The shares recently traded near $9.38, toward the lower end of a 52-week range of roughly $8.40 to $15.18 and down about 39% from their high. Reaching $11 would require a move of approximately 17% — a substantial, though not extreme, repricing for a BDC. That is roughly the magnitude of the stock's discount to NAV closing by a modest amount, since CCAP's net asset value per share stood at $17.72 at September 30, 2026. The shares therefore trade near half of book value, an unusually deep discount that frames the entire debate: the target is reachable chiefly if investors begin to believe the stated book value is durable.
What Could Support a Move Toward the Target
Several verified factors could help. The company announced a $50 million share repurchase program on November 5, 2026, which buys back shares at roughly half of NAV and is accretive to NAV per share. Management also permanently reduced base and incentive fees effective April 2026, improving dividend coverage. Non-accruals — loans where borrowers have stopped paying — eased from 5.7% to 4.8% of the debt portfolio in the second quarter, a sign of stabilizing credit. The portfolio is diversified across roughly 190 companies, with about 90% in first-lien senior secured loans, and parent Sun Life holds a meaningful stake. Any evidence of NAV stabilization or narrower discounting would support the path toward $11. From what I see, this setup stands out as a key support.
What Could Prevent the Target From Being Reached
The risks are equally concrete. Net asset value per share has fallen from $19.10 at the end of 2025 to $17.72, eroded by realized losses and markdowns, and the base dividend was cut 19%, from $0.42 to $0.34 per quarter, because net investment income (NII) had slipped. Third-quarter NII of $0.37 per share covers the $0.34 dividend only thinly. The weighted-average yield on income-producing securities has declined as floating-rate loans reset lower, and persistent credit deterioration would further erode book value and keep the deep discount intact. More analyst target reductions would also weigh on sentiment.
Technical Levels and Market Structure
The 52-week low near $8.40 is the key support level to watch; a decisive break below it would signal renewed deterioration. On the upside, the round-number $10 mark — where several analyst targets and prior support levels sit — is the first resistance zone, followed by the $12 level that marks the top of the recent analyst range. The shares remain in a longer-term downtrend from the mid-teens, so sustained upside would likely require the stock to reclaim $10 and hold it. I’m watching this closely for any shifts in momentum.
Time Horizon and What Investors Should Monitor
Analyst price targets for BDCs generally reflect a research horizon of about 12 months, though individual firms do not always state it explicitly and the target revisions here have been unusually frequent. Investors should monitor quarterly NAV per share, the non-accrual and watch-list trends, NII versus the $0.34 dividend, execution of the buyback, and any further analyst revisions. Interest-rate policy from the Federal Reserve remains relevant, since lower rates pressure yields on the floating-rate loan portfolio. The next quarterly earnings report and management's commentary on credit quality are the most direct catalysts.
Final Assessment
Whether CCAP can reach $11 depends less on dramatic growth than on whether investors begin to trust its $17.72 net asset value. The central target — an average of the five most recent analyst targets, ranging from $10 to $12 — requires about 17% upside, a substantial move that would still leave the stock at a wide discount to book. The $50 million buyback, fee reductions, and improving non-accrual trend support the case, while eroding NAV, thin dividend coverage, and credit risk argue for caution. Analysts' recent downgrades and target cuts show real disagreement beneath the surface. The most important signals ahead are quarterly NAV, credit metrics, and buyback execution; none of these guarantees the target will be reached.
Exploring AI Daily Buy/Sell Signals for Additional Perspective
For traders seeking a systematic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening allows. Exploring these signals can add a data-driven layer to any outlook on CCAP. In my view, this approach has become a useful part of my routine for staying on top of names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CCAP in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 16, 2026
CCAP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 21 of 33 cases where CCAP's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CCAP as a result. In 46 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for CCAP just turned positive on October 27, 2026. Looking at past instances where CCAP's MACD turned positive, the stock continued to rise in 23 of 43 cases over the following month. The odds of a continued upward trend are 53%.
CCAP moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCAP advanced for three days, in 174 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The 10-day RSI Indicator for CCAP moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 16 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCAP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for CCAP entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. CCAP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.526) is normal, around the industry mean (2.412). P/E Ratio (-104.222) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (0.892) is also within normal values, averaging (1.319). Dividend Yield (0.145) settles around the average of (0.270) among similar stocks. P/S Ratio (51.282) is also within normal values, averaging (15.694).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which invests in secured and unsecured debt and related equity securities.
Industry InvestmentManagers
Advertisement